Skip to main content
Equibles
PMI logo

PMI · Picard Medical, Inc. · Metrics

Track PMI — free

Use PMI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PMI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.33 +0.92 (+20.86%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this filing are issued.”
View the 10-Q filed Aug 19, 2026
Market Cap
$10.31M
Shares
2.34M

PMI metrics

46 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.33
Market cap
$10.31M

Price action

20 metrics
Price change (1W)
-1.8%
Price change (30D)
+25.6%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
43.2
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
3.21M
Relative volume
0.1
Average dollar volume
$23.03M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
2.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.6×
reciprocal yield 61.0%
P / book
6.0
reciprocal yield 16.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-271.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-25

Profitability

9 metrics
Gross margin
18.6%
Operating margin
-248.4%
Trailing 12 months
Net margin
-444.8%
Gross profit (TTM)
$1.17M
Operating profit (TTM)
−$15.63M
Net income (TTM)
−$27.99M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$128.53

Growth

11 metrics
Revenue growth YoY
+38.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$6.29M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+356.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,631.3%
Return on assets
-305.4%
Debt / equity
—
Current ratio
1.0
EBITDA (TTM)
−$15.46M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$38,000
Total assets
$9.17M
Total debt
$1.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$16.04M
Capital expenditures (TTM)
—
R&D (TTM)
$4.77M
SG&A (TTM)
$12.04M
Stock compensation (TTM)
$1.98M
R&D / revenue
75.8%
Stock compensation / revenue
31.4%

Ownership (13F)

3 metrics
13F filers
40
13F filer change QoQ
-1
Institutional ownership
6.5%

Short interest

3 metrics
Short interest
15.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 2030617 CUSIP 71953R108 13F (30d) 18 filings 18 filers Visit website